GlaxoSmithKline Boosts Stake In Theravance To 27% – NASDAQ


RTT News

GlaxoSmithKline Boosts Stake In Theravance To 27%
NASDAQ
The move is said to be on the potential success of asthma drug Relovair, which is believed to be the successor of Seretide/Advair that logged sales of roughly $8.1 billion in 2011. Relovair is developed by Theravance and GlaxoSmithKline and is a
GlaxoSmithKline to Increase Its Ownership in TheravanceMarketWatch (press release)
GlaxoSmithKline invests $213M in Theravance Inc.Triangle Business Journal
Glaxo Lifts Theravance StakeWall Street Journal
MedCity News
all 34 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.